CSPC Pharmaceutical (HKG:1093) said a phase 2/3 trial of its KN026 anti-cancer drug met the primary endpoint of progression-free survival, according to a Wednesday filing with the Hong Kong bourse.
The drug, which treats patients with human epidermal growth factor receptor 2-positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma, is developed by Shanghai JMT-Bio Technology and Jiangsu Alphamab Oncology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.